Olema Pharmaceuticals (OLMA) to Release Quarterly Earnings on Tuesday

Olema Pharmaceuticals (NASDAQ:OLMA) will likely be posting its Q4 2025 results before the market opens on Tuesday, March 17th. Analysts expect Olema Pharmaceuticals to post earnings of ($0.51) per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 20, 2026 at 4:00 PM ET.

Olema Pharmaceuticals Stock Performance

Shares of OLMA stock opened at $16.00 on Tuesday. The stock has a fifty day moving average price of $24.97 and a 200 day moving average price of $18.31. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.03 and a current ratio of 8.03. The stock has a market cap of $1.10 billion, a PE ratio of -8.56 and a beta of 1.93. Olema Pharmaceuticals has a 1 year low of $2.86 and a 1 year high of $36.26.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Piper Sandler started coverage on Olema Pharmaceuticals in a research report on Wednesday, January 7th. They issued an “overweight” rating and a $40.00 price target for the company. Stifel Nicolaus started coverage on shares of Olema Pharmaceuticals in a research report on Wednesday, February 11th. They issued a “buy” rating and a $48.00 price objective on the stock. JPMorgan Chase & Co. raised their target price on shares of Olema Pharmaceuticals from $29.00 to $32.00 and gave the company an “overweight” rating in a report on Tuesday, November 18th. Oppenheimer restated an “outperform” rating on shares of Olema Pharmaceuticals in a research report on Monday. Finally, HC Wainwright reduced their price target on shares of Olema Pharmaceuticals from $45.00 to $38.00 and set a “buy” rating on the stock in a report on Monday. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Olema Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $41.00.

Insiders Place Their Bets

In related news, insider Naseem Zojwalla sold 99,509 shares of the stock in a transaction on Tuesday, December 23rd. The stock was sold at an average price of $27.66, for a total transaction of $2,752,418.94. Following the sale, the insider owned 4,488 shares of the company’s stock, valued at $124,138.08. This trade represents a 95.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Cyrus Harmon sold 10,000 shares of Olema Pharmaceuticals stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $26.88, for a total value of $268,800.00. Following the sale, the director owned 727,770 shares of the company’s stock, valued at approximately $19,562,457.60. This represents a 1.36% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 805,501 shares of company stock valued at $23,003,832. Insiders own 16.36% of the company’s stock.

Institutional Investors Weigh In On Olema Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Invesco Ltd. raised its position in shares of Olema Pharmaceuticals by 25.0% in the fourth quarter. Invesco Ltd. now owns 155,732 shares of the company’s stock valued at $3,893,000 after buying an additional 31,098 shares during the last quarter. EP Wealth Advisors LLC purchased a new position in shares of Olema Pharmaceuticals during the fourth quarter valued at approximately $250,000. Vestal Point Capital LP acquired a new stake in Olema Pharmaceuticals during the fourth quarter worth approximately $41,250,000. Wellington Management Group LLP boosted its position in Olema Pharmaceuticals by 8.2% during the fourth quarter. Wellington Management Group LLP now owns 220,971 shares of the company’s stock worth $5,524,000 after acquiring an additional 16,764 shares during the last quarter. Finally, Perceptive Advisors LLC purchased a new stake in Olema Pharmaceuticals in the 4th quarter worth approximately $4,143,000. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.